Regenxbio Inc RGX-314 Update Call Transcript
Good morning, and welcome to the REGENXBIO conference call to provide updates from the RGX-314 wet AMD program. (Operator Instructions) As a reminder, this conference call is being recorded. (Operator Instructions) I would now like to turn the conference over to Mr. Patrick Christmas, Chief Legal Officer for REGENXBIO. You may begin.
Good morning, and thank you for joining us today. Earlier this morning, REGENXBIO provided an update via press release, which is available on our website at www.regenxbio.com. We will also be reviewing slides during this call, which you can access via the Investors Section of our website.
Today's conference call will include forward-looking statements regarding our clinical development of RGX-314, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasts and can be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |